专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019075055A1 METHODS OF PRODUCING T CELL POPULATIONS USING P38 MAPK INHIBITORS 审中-公开
公开(公告)号：WO2019075055A1
公开(公告)日：2019-04-18
申请号：PCT/US2018/055206
申请日：2018-10-10
申请人： THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , KUMAR, Shashankkumar, J. , RESTIFO, Nicholas, P.
发明人： KUMAR, Shashankkumar, J. , RESTIFO, Nicholas, P.
IPC分类号： C12N5/0783 , C12N9/12
CPC分类号： C12N9/1205 , C12N5/0636 , C12N2501/727 , C12N2510/00
摘要： Provided are methods of producing an isolated population of T cells for adoptive cell therapy, the method comprising culturing isolated T cells in vitro in the presence of a p38 mitogen activated protein kinase (p38 MAPK) inhibitor, wherein the T cells have antigenic specificity for a cancer antigen. Also provided are related isolated populations of T cells, pharmaceutical compositions, and methods of treating or preventing cancer in a mammal.

2. 发明申请

WO2019055325A2 BIOLOGICAL DEVICES AND METHODS FOR USING THE SAME TO PRODUCE STEVIOL GLYCOSIDES 审中-公开
公开(公告)号：WO2019055325A2
公开(公告)日：2019-03-21
申请号：PCT/US2018/050143
申请日：2018-09-10
申请人： BIOCAPITAL HOLDINGS, LLC
发明人： CUERO RENGIFO, Raul
IPC分类号： A01H6/14 , C12N15/82
CPC分类号： C12N15/8246 , C07K14/395 , C12N1/18 , C12N9/1022 , C12N9/1051 , C12N9/1085 , C12N9/1205 , C12N9/88 , C12N9/90 , C12N15/52 , C12N15/63 , C12N15/8243 , C12P19/56
摘要： Described herein are devices and methods for increasing the production of steviol glycosides, which have industrial and economic value. The steviol glycosides produced by the devices and methods disclosed herein do not require the ultra purification that is common in conventional or commercial methods and do not have a bitter aftertaste, making them better suited as flavor-enhancing additives to food, pharmaceutical, and nutritional supplement products.

3. 发明申请

WO2017177071A1 IMPROVED GALACTOSE UTILIZATION 审中-公开
标题翻译：改进的半乳糖利用
公开(公告)号：WO2017177071A1
公开(公告)日：2017-10-12
申请号：PCT/US2017/026463
申请日：2017-04-06
申请人： WILLIAM MARSH RICE UNIVERSITY
发明人： SAN, Ka, Yiu , LIU, Ping , LI, Sha
IPC分类号： C12N1/20 , C12N1/21 , C12N15/00 , C12N15/63
CPC分类号： C12N15/52 , C12N1/20 , C12N9/1205 , C12N15/63 , C12N15/70 , C12N15/74 , C12P1/04 , C12P7/16 , C12P7/46 , C12P7/6409 , C12Y207/01006 , Y02E50/10
摘要： The present disclosure describes a genetically engineered bacteria that relieves the catabolite repression problem exerted by the Spot 42 small regulatory RNA by adding a galactokinase that does not contain the Spot 42 binding region. As such, galK and galM and the like can be expressed allow better galactose utilzation.
摘要翻译：本公开描述了通过添加不包含Spot 42结合区域的半乳糖激酶来缓解Spot 42小调控RNA所施加的分解代谢物抑制问题的基因工程细菌。同样地，可以表达galK和galM等以允许更好的半乳糖利用。

4. 发明申请

WO2017167660A1 USE OF GLUCOSE DEFICIENT STREPTOCOCCUS THERMOPHILES STRAINS IN A PROCESS FOR PRODUCING FERMENTED MILK PRODUCTS 审中-公开
标题翻译：葡萄糖缺陷型链球菌热亲和菌株在生产发酵乳产品的过程中的应用
公开(公告)号：WO2017167660A1
公开(公告)日：2017-10-05
申请号：PCT/EP2017/057083
申请日：2017-03-24
申请人： CHR. HANSEN A/S
发明人： CHRISTENSEN, Nanna , HOEGHOLM, Tina , JENSEN, Pia Frost , SVANE, Claus
IPC分类号： A23C9/12 , A23C9/127 , A23C19/032 , A23C17/02 , A23C9/123 , C12N1/20 , C12N9/12
CPC分类号： C12N9/1205 , A23C9/1234 , A23C9/1238 , A23C19/0684 , A23Y2240/75 , C07K14/315 , C12N1/20 , C12R1/225 , C12R1/23 , C12R1/46
摘要： The invention relates to the use of a Streptococcus thermophilus strain with a deficiency in glucose metabolism for improving growth of a Lactobacillus strain in a process for producing a fermented milk product.
摘要翻译：本发明涉及具有缺乏葡萄糖代谢的嗜热链球菌菌株在用于改进乳杆菌属菌株生长的方法中的用途，生产发酵奶产品。

5. 发明申请

WO2017103051A1 LACTIC ACID BACTERIA FOR PREPARING FERMENTED FOOD PRODUCTS WITH INCREASED NATURAL SWEETNESS AND HIGH TEXTURE 审中-公开
标题翻译：用于制备具有增加的天然甜味和高度纹理的发酵食品的乳酸菌
公开(公告)号：WO2017103051A1
公开(公告)日：2017-06-22
申请号：PCT/EP2016/081361
申请日：2016-12-16
申请人： CHR. HANSEN A/S
发明人： BUCHHORN, Gaelle Lettier , SOERENSEN, Kim Ib , JUNGE, Mette Pia
IPC分类号： A23C9/123 , C12R1/46 , C12N15/01
CPC分类号： A23C9/1238 , A23C2220/206 , A23Y2240/75 , C12N1/20 , C12N9/1205 , C12Y207/01002 , C12Y207/01006
摘要： The present invention relates to a Streptococcus thermophilusstrain, wherein the strain is galactose-fermenting, wherein the straincarries a mutation in the DNA sequence of the glcKgene encoding a glucokinase protein, wherein the mutation inactivates the glucokinase protein or has a negative effect on expression of the gene, and wherein the strain carries a mutation in the promoter region of the GalK geneencoding a galactokinase protein.
摘要翻译：本发明涉及嗜热链球菌菌株，其中所述菌株是半乳糖发酵，其中所述菌株携带编码葡萄糖激酶蛋白的glcK基因的DNA序列中的突变，其中所述突变使葡糖激酶蛋白失活或对基因的表达具有负面影响，并且其中该菌株在编码半乳糖激酶蛋白质的GalK基因的启动子区域携带突变。

6. 发明申请

WO2017082942A1 COMPOSITIONS AND METHODS FOR MODULATING KINASE ACTIVITY 审中-公开
标题翻译：调节激酶活性的组合物和方法
公开(公告)号：WO2017082942A1
公开(公告)日：2017-05-18
申请号：PCT/US2016/015171
申请日：2016-01-27
申请人： BRANDEIS UNIVERSITY
发明人： KERN, Dorothee , ZORBA, Adelajda
IPC分类号： C07K17/00 , C12P21/06
CPC分类号： C12N15/62 , A61K38/00 , C07K14/47 , C07K16/40 , C07K2317/76 , C07K2319/10 , C07K2319/20 , C12N9/1205 , C12Q1/485 , G01N2500/04
摘要： The present invention features an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, therapeutic compositions comprising this antibody mimetic, and the use of the monobody to modulate Aurora A kinase for the treatment of cancer.
摘要翻译：本发明的特征在于特异性结合Aurora A激酶的变构位点的抗体模拟物或其抗原结合片段，包含该抗体模拟物的治疗性组合物，以及该单体调节 Aurora A激酶用于治疗癌症。

7. 发明申请

WO2017060195A1 EUKARYOTIC CELL WITH INCREASED PRODUCTION OF FERMENTATION PRODUCT 审中-公开
标题翻译：原始细胞增加发酵产品的生产
公开(公告)号：WO2017060195A1
公开(公告)日：2017-04-13
申请号：PCT/EP2016/073561
申请日：2016-10-03
申请人： DSM IP ASSETS B.V.
发明人： PAPAPETRIDIS, Ioannis , PRONK, Jacobus, Thomas , VAN MARIS, Antonius, Jeroen, Adriaan , KLAASSEN, Paul
IPC分类号： C12N9/04 , C12N9/02 , C12N9/12 , C12N9/18 , C12N9/00 , C12P7/06 , C12P7/10
CPC分类号： C12N9/0006 , C12N9/0008 , C12N9/1205 , C12N9/18 , C12N9/93 , C12N15/52 , C12P7/10 , C12P2203/00 , C12Y101/01008 , C12Y101/01044 , C12Y101/01049 , C12Y101/05003 , C12Y101/99 , C12Y102/0101 , C12Y301/03021 , C12Y503/01005 , C12Y602/0101
摘要： The present invention relates to a eukaryotic cell that is genetically modified comprising one or more heterologous gene encoding: a) D-glucose-6-phosphate dehydrogenase and/or b) 6-phosphogluconate dehydrogenase; and/or c) glucose dehydrogenase, gluconolactonase and gluconate kinase, wherein a), b) and glucose dehydrogenase in c) are NAD+ dependent.
摘要翻译：本发明涉及经遗传修饰的真核细胞，其包含一个或多个异源基因，其编码：a）D-葡萄糖-6-磷酸脱氢酶和/或b）6-磷酸葡萄糖酸脱氢酶; 和/或c）葡萄糖脱氢酶，葡萄糖酸内切酶和葡萄糖酸激酶，其中a），b）和c）中的葡萄糖脱氢酶是NAD +依赖性的。

8. 发明申请

WO2017014865A1 NUTRITIONAL COMPOSITIONS COMPRISING HYDROLYSED CASEIN 审中-公开
标题翻译：包含水解产品的营养组合物
公开(公告)号：WO2017014865A1
公开(公告)日：2017-01-26
申请号：PCT/US2016/037330
申请日：2016-06-14
申请人： MJN U.S. HOLDINGS LLC
发明人： LAMBERS, Teartse Tim, , VAN TOL, Eric A.F., , MANURUNG, Sarmauli,
IPC分类号： A61K38/01 , A61K38/04 , A61K38/07 , A61K38/08 , C12N9/12 , A23L33/18 , A23L33/19 , A23L33/00 , A61P37/00
CPC分类号： A61K38/018 , A23L33/18 , A23L33/19 , A23L33/40 , A23V2002/00 , A61K31/202 , A61K31/702 , A61K31/716 , A61K35/74 , A61K35/741 , C07K14/4732 , C12N9/1205 , C12Y207/01 , A23V2200/30 , A23V2200/304 , A23V2200/32 , A23V2200/324 , A23V2250/00 , A23V2250/54246 , A23V2250/55 , A23V2300/00 , A23V2300/28 , A61K2300/00
摘要： A method for modulating a kinase by administering to a subject a nutritional composition comprising extensively hydrolyzed casein, extensively hydrolyzed casein fractions, or combinations thereof. A modulated kinase may be a kinase that regulates inflammatory signaling, immune tolerance, metabolic signaling, cell cycle and growth factor signaling. The nutritional composition may dose-dependently inhibit a range of serine, threonine and tyrosine kinases.
摘要翻译：通过向受试者施用包含广泛水解的酪蛋白，广泛水解的酪蛋白级分或其组合的营养组合物来调节激酶的方法。调节的激酶可以是调节炎症信号，免疫耐受，代谢信号，细胞周期和生长因子信号传导的激酶。营养组合物可以剂量依赖地抑制丝氨酸，苏氨酸和酪氨酸激酶的范围。

9. 发明申请

WO2017009790A1 ENHANCING MICROALGAL METABOLISM OF XYLOSE 审中-公开
标题翻译：增强XYLOSE的微量代谢
公开(公告)号：WO2017009790A1
公开(公告)日：2017-01-19
申请号：PCT/IB2016/054185
申请日：2016-07-13
申请人： MARA RENEWABLES CORPORATION
发明人： MERKX-JACQUES, Alexandra , WOODHALL, David , SCAIFE, Mark , ARMENTA, Roberto E. , MUISE, Denise , RASMUSSEN, Holly , BENJAMIN, Jeremy
IPC分类号： C12N1/11 , C07K14/40 , C11C1/00 , C12N15/31 , C12N15/54 , C12N15/61
CPC分类号： C12N9/92 , C07K14/40 , C07K2319/21 , C12N9/1205 , C12Y207/01017 , C12Y503/01005
摘要： Provided herein are recombinant microorganisms having two or more copies of a nucleic acid sequence encoding xylose isomerase, wherein the nucleic acid encoding the xylose isomerase is an exogenous nucleic acid. Optionally, the recombinant microorganisms include at least one nucleic acid sequence encoding a xylulose kinase and/or at least one nucleic acid sequence encoding a xylose transporter. The provided recombinant microorganisms are capable of growing on xylose as a carbon source.
摘要翻译：本文提供了具有两个或更多拷贝的编码木糖异构酶的核酸序列的重组微生物，其中编码木糖异构酶的核酸是外源核酸。任选地，重组微生物包括编码木酮糖激酶和/或编码木糖转运蛋白的至少一个核酸序列的至少一个核酸序列。所提供的重组微生物能够在作为碳源的木糖上生长。

10. 发明申请

WO2016166171A1 MUTANT HUMAN DEOXYCYTIDINE KINASE 审中-公开
标题翻译： MUTANT人类去氧霉素激酶
公开(公告)号：WO2016166171A1
公开(公告)日：2016-10-20
申请号：PCT/EP2016/058137
申请日：2016-04-13
申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITÉ DE STRASBOURG
发明人： COULIBALY, Safiatou , ROSSOLILLO, Paola , NEGRONI, Matteo
IPC分类号： C12N9/12
CPC分类号： C12N9/1205 , A61K31/7068 , A61K38/45 , A61K48/00 , A61P31/12 , A61P35/00 , C12Q1/6897 , C12Y207/01073 , C12Y207/01074
摘要： The present invention concerns an isolated nucleic acid comprising a sequence encoding a mutant human deoxycytidine kinase (hdCK) capable of converting prodrugs, such as a nucleoside analogue, into cytotoxic drugs. The invention further refers to an isolated vector comprising said nucleic acid of the invention and an isolated host cell genetically engineered with said isolated vector. The invention also refers to a procedure for producing such polypeptides by recombinant techniques. The invention further refers to a pharmaceutical composition comprising an isolated nucleic acid, an expression vector, a host cell, or an isolated mutant hdCK of the invention. Their use as a medicament or their use as a medicament for the treatment of cancer or for the prevention of a viral infection is also part of the invention. The invention further refers to methods for utilizing such polypeptides for the treatment of malignancies and viral infections, methods of sensitizing cells to prodrugs, methods of gene therapy, methods of non-invasive nuclear imaging and methods of inhibiting pathogenic agents in a subject using said mutant hdCK.
摘要翻译：本发明涉及分离的核酸，其包含编码能够将前药如核苷类似物转化为细胞毒性药物的突变型人脱氧胞苷激酶（hdCK）的序列。本发明还涉及包含本发明的所述核酸的分离的载体和用所述分离的载体进行遗传工程改造的分离的宿主细胞。本发明还涉及通过重组技术产生此类多肽的方法。本发明还涉及包含本发明的分离的核酸，表达载体，宿主细胞或分离的突变体hdCK的药物组合物。它们作为药物的用途或其用作治疗癌症或用于预防病毒感染的药物的用途也是本发明的一部分。本发明还涉及利用这些多肽来治疗恶性肿瘤和病毒感染的方法，使细胞对前药敏感的方法，基因治疗方法，非侵入性核成像方法以及使用所述突变体在受试者中抑制病原体的方法 hdCK。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式